USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AUXAGEN, INC.
Address:
AUXAGEN, INC.
7 PRICEWOODS
SAINT LOUIS, MO
Phone:
N/A
URL:
N/A
EIN:
201337535
DUNS:
153650655
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $403,172.00 2
SBIR Phase II $998,034.00 1
STTR Phase I $381,656.00 2

Award List:

TGF-Beta Antagonists for Accelerating Wound Healing

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$175,480.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Impaired or abnormal wound healing is a major health problem for elderly, diabetic, immunosuppressed, immobilized, burn-injured and keloid individuals. Every year in the United States, 6.5 million people have chronic skin ulcers caused by pressure, venous stasis… More

Novel Antagonists for Ameliorating Pulmonary Fibrosis

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$199,467.00
Agency:
HHS
Principal Investigator:
Research Institution:
ST. LOUIS UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Pulmonary fibrosis, a group of incurable lung diseases with high mortality rates, is characterized by inflammatory cell infiltration, fibroblast proliferation, and excessive deposition of extracellular matrix proteins i n lung parenchyma. Globally, five million… More

Novel Therapeutic Agents for Diabetic Ulcers

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$182,189.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Diabetes mellitus afflicts 20.8 million people, or 7% of the population, in the United States. Fifteen percent, or 2.4 million people, will develop diabetic foot ulcers in their life time. Diabetic foot ulceration and i nfections are a major cause of… More

A Therapeutic Agent for Radiation-induced Lung Fibrosis

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$227,692.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Lung fibrosis, a group of incurable lung diseases with high mortality rates, is characterized by inflammatory cell infiltration, fibroblast proliferation, and excessive deposition of extracellular matrix proteins (ECM) in lung parenchyma. Globally, five million… More

TGF-beta Antagonists for Accelerating Wound Healing

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$998,034.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Every year in the United States, gt1.25 million people suffer from burns, 6.5 million have chronic skin ulcers caused by pressure, venous stasis or diabetes mellitus and 0.25 million have keloids sufficiently severe to require surgery. Burn treatment costs 1.8… More